Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad exposure to this emergent industry. During the past 12 months, OXB has effectively doubled its CDMO partner programmes to 20, while broadening its own gene therapy R&D portfolio offering. Partner Axovant expects to report six-month efficacy data on AXO-Lenti-PD (end
05 Oct 2020
Oxford Biomedica - Vector innovation key to cell and gene evolution
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oxford Biomedica - Vector innovation key to cell and gene evolution
Oxford BioMedica plc (OXB:LON) | 202 -5.1 (-1.2%) | Mkt Cap: 202.5m
- Published:
05 Oct 2020 -
Author:
Dr Susie Jana -
Pages:
21
Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical component of cell and gene therapies (CGTs). An investment in OXB gives a broad exposure to this emergent industry. During the past 12 months, OXB has effectively doubled its CDMO partner programmes to 20, while broadening its own gene therapy R&D portfolio offering. Partner Axovant expects to report six-month efficacy data on AXO-Lenti-PD (end